Coephycient Pharmaceutical Consultancy Report issue

For profit Phase 3
Founded: Guildford United Kingdom (2001)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2014
NCT02260791
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

adalimumab (humira) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 3)

Arthritis, Rheumatoid (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 1